Skip to content
HowShorted

Oric Pharmaceuticals, Inc. short interest in 2022

In 2022, Oric Pharmaceuticals, Inc.'s disclosed short interest ran from 6.30% of shares outstanding on 14 Jan 2022 to 8.94% on 30 Dec 2022, a change of +2.64 percentage points. The year's high was 12.37% on 13 May 2022 and its low 6.15% on 15 Dec 2022, averaging 7.78% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 49.07 days on 31 Oct 2022. Full history: Oric Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Oric Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
6.30% (14 Jan 2022)
End of year
8.94% (30 Dec 2022)
Change
+2.64 pp
High
12.37% (13 May 2022)
Low
6.15% (15 Dec 2022)
Average
7.78%
Highest days to cover
49.07 (31 Oct 2022)
SEC filings marked
9

Every report in 2022

Oric Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.30%14.17results (8-K)
31 Jan 20227.17%12.21
15 Feb 20228.06%16.10
28 Feb 20228.89%15.78
15 Mar 20228.50%11.45
31 Mar 20226.47%1.5910-K filed, results (8-K)
14 Apr 20226.74%3.70
29 Apr 20228.93%6.88
13 May 202212.37%10.6510-Q filed, results (8-K)
31 May 202211.35%10.23
15 Jun 202211.06%14.14
30 Jun 20227.70%3.96
15 Jul 20227.21%17.47
29 Jul 20227.05%21.88
15 Aug 20226.97%14.2110-Q filed, results (8-K)
31 Aug 20226.75%47.63
15 Sep 20226.82%36.14
30 Sep 20226.83%13.78
14 Oct 20226.75%45.73
31 Oct 20226.70%49.07
15 Nov 20226.68%44.2910-Q filed, results (8-K)
30 Nov 20226.25%20.02
15 Dec 20226.15%31.43
30 Dec 20228.94%1.00

See also: Oric Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.